Merck re-ups on biosimilars

Merck KGaA (Xetra:MRK) said it would invest EUR 130-EUR 150 million ($168.2-$194.1 million) in biosimilars during 2015, depending on the outcome of ongoing Phase I studies. The investment comes on top of a EUR 100 million commitment in 2014.

The pharma also said it had in-licensed an undisclosed late-stage biosimilar, which it will develop for smaller emerging markets. ...